GLEN ALLEN, Va., Feb. 14, 2014 /PRNewswire/ -- Star Scientific,
Inc., (NASDAQ: STSI) today announced that the Company will host an
Analyst and Investor meeting for research analysts, and
institutional and other investors, on Thursday, March 20, 2014, from 1:00 PM (EDT) to 3:00 PM in Sarasota, Florida, at the Roskamp
Institute. Michael Mullan,
M.D.(MBBS), Ph.D., Chairman and Chief Executive Officer of Star
Scientific, along with Chris
Chapman, M.D., President, will lead the Company's
presentations. The presentations will focus on the scientific
foundations of the Company's technology, the progress of its
research and development programs, and the Company's near-term and
long-term pharmaceutical strategy.
(Logo:
http://photos.prnewswire.com/prnh/20130319/PH79245LOGO )
A live video webcast of the Analyst and Investor meeting will be
accessible to the public through the Investor Relations section of
Star Scientific's website at:
http://www.starscientific.com/investors. Instructions
relating to the electronic submission of questions from the webcast
audience will be provided on the Company website as the meeting
date approaches.
Registration is required to attend the meeting in Sarasota and seating is limited.
Individuals interested in attending the meeting in person will be
able to register, beginning February 19,
2014, through a link on the Company's website
(www.starscientific.com).
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and market acceptance of our
nutraceutical dietary supplements products, the effect of any
competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in
the future that is necessary to maintain our business, changes in
government policy and/or regulation, potential litigation by or
against us, any governmental review of our products or practices
and the outcome of the ongoing investigations as well as other
risks discussed from time to time in our filings with the
Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended
December 31, 2012 and our quarterly
reports on Form 10-Q for the quarters ended March 31, 2013, June 30,
2013, and September 30, 2013.
We undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public
disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a
mission to promote maintenance of a healthy metabolism and
lifestyle. Through its wholly owned subsidiary, Rock Creek
Pharmaceuticals, Star Scientific has been engaged in the
manufacturing, sale, and marketing of two nutraceutical dietary
supplements, a cosmetic facial cream, a facial serum, and the
development of other nutraceuticals and pharmaceuticals. The
company also continues to pursue the licensing of the technology
behind its proprietary StarCured® curing process and its related
products.
CONTACT:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(202) 887-5100
ttuck@starscientific.com
Ted Jenkins
Vice President, Corporate Strategy and Development
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharmaceuticals.com
SOURCE Star Scientific, Inc.